Compare Arm Holdings plc (ARM) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs Biogen Inc — how do they compare? Arm Holdings plc trades at $313.44 (market cap $345.41B), while Biogen Inc trades at $201 (market cap $29.40B). The key difference: Arm Holdings plc is far larger — about 11.7× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | BIIB | |
|---|---|---|
Market Cap | $345.41B | $29.40B |
Sector | Technology | Health |
52-Week High | $439.46 | $216.63 |
52-Week Low | $104.55 | $122.68 |
Enterprise Value | $342.26B | $31.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Biogen (BIIB) trades at $199.15, up 0.12% on the day, with a bullish technical signal from moving averages and RSI near oversold levels at 20.73. The company reported Q1 2026 EPS of $3.57, beating estimates of $3.05, continuing a trend of earnings surprises. Revenue for 2025 was $9.89B with a net income margin of 13.81%, while recent acquisitions like RayThera for up to $1B aim to bolster its immunology pipeline. Analyst consensus price target is $226.00, implying potential upside from current levels.
BIIB presents a mixed outlook with strong earnings momentum and strategic acquisitions offset by legacy drug sales declines and legal investigations. The stock's valuation at a P/E of 21.41 is reasonable relative to growth prospects, but investors face risks from pipeline execution and competitive pressures in biotech. Near-term catalysts include Alzheimer's data presentations at AAIC 2026 in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
